There is now overwhelming evidence to support lowering LDL-c (low-density lipoprotein
cholesterol) to reduce cardiovascular morbidity and mortality. Statins are a class of drugs …

Most disease-associated variants, although located in putatively regulatory regions, do not
have detectable effects on gene expression. One explanation could be that we have not …

Abstract Treatment with statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A
reductase, has proven beneficial preventive effects on cardiovascular events. However …

Statins are a family of drugs that are used for treating hyperlipidaemia with a recognized
capacity to prevent cardiovascular disease events. They inhibit β‐hydroxy β‐methylglutaryl …

Hyperlipidemia is a major risk factor for cardiovascular morbidity and mortality. Statins are
the first-choice therapy for dyslipidemias and are considered the cornerstone of …

Statin-associated muscle symptoms (SAMS) are one of the principal reasons for statin non-
adherence and/or discontinuation, contributing to adverse cardiovascular outcomes. This …

Explaining the genetics of many diseases is challenging because most associations localize
to incompletely characterized regulatory regions. Using new computational methods, we …

We are in a phase of unprecedented progress in identifying genetic loci that cause variation
in traits ranging from growth and fitness in simple organisms to disease in humans …

Statins, inhibitors of the hydroxymethylglutaryl-CoA (HMG-CoA) reductase enzyme, are
molecules of fungal origin. By inhibiting a key step in the sterol biosynthetic pathway statins …

We conducted a genome-wide association analysis of 7 subfractions of low density
lipoproteins (LDLs) and 3 subfractions of intermediate density lipoproteins (IDLs) measured …